Business Context and Reporting Period
This Form 6-K filing by Jin Medical International Ltd. covers the month of July 2026. The report discloses corporate governance changes, specifically the resignation of an independent director and the appointment of a successor to fill the vacancy.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to corporate governance disclosures and does not contain financial performance data.
Material Changes
- Resignation: Dr. Jiayuan (James) Tong resigned as an independent director, Chairperson of the Nominating and Corporate Governance Committee, and member of the Audit, Compensation, and Nominating and Corporate Governance Committees, effective July 9, 2026.
- Reason for Resignation: The resignation was not the result of any disagreement with the Company regarding operations, policies, or practices.
- Appointment: Mr. Ning Xue was appointed as an independent director effective July 14, 2026. He was also appointed Chairperson of the Nominating and Corporate Governance Committee and a member of the Audit and Compensation Committees.
Outlook, Risks, and Unusual Items
Management Commentary and Compensation: Mr. Xue will serve an initial term from July 14, 2026, to March 27, 2027. His compensation is set at US$14,082 for the term, payable in quarterly installments, plus reimbursement of reasonable expenses. The Board confirmed Mr. Xue meets Nasdaq independence requirements and Rule 10A-3 requirements for Audit Committee members.
Risks and Contingencies: No specific financial risks or contingencies were disclosed in this filing. The Company entered into an Independent Director Agreement and an Indemnification Agreement with Mr. Xue.
Key Facts for Investor Verification
- Verify the independence status and background of the newly appointed director, Mr. Ning Xue, particularly his prior role at TIAN RUIXIANG Holdings Ltd.
- Confirm the total annualized cost of the new director appointment (US$14,082 for approximately 8 months).
- Review the full text of the Independent Director Agreement (Exhibit 10.1) and Indemnification Agreement (Exhibit 10.2) for specific liability terms.
- Monitor future filings for any financial impact related to the governance transition, though none is expected to be material.